A5074208719- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- HIV/AIDS drug development and treatment
- CNS Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Histiocytic Disorders and Treatments
- HIV Research and Treatment
- Immune Cell Function and Interaction
- HIV/AIDS Research and Interventions
- Cytomegalovirus and herpesvirus research
- Parvovirus B19 Infection Studies
- Gestational Trophoblastic Disease Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Polyomavirus and related diseases
- Photoacoustic and Ultrasonic Imaging
- Cardiovascular Disease and Adiposity
- Angiogenesis and VEGF in Cancer
- Herpesvirus Infections and Treatments
- Optical Coherence Tomography Applications
- Eosinophilic Disorders and Syndromes
- T-cell and Retrovirus Studies
- Optical Polarization and Ellipsometry
- Spectroscopy Techniques in Biomedical and Chemical Research
Center for Cancer Research
2007-2023
National Cancer Institute
2006-2019
National Institutes of Health
2006-2019
Office of AIDS Research
2018
Leidos (United States)
2017
Frederick National Laboratory for Cancer Research
2017
National Institute of Allergy and Infectious Diseases
2000-2016
AIDS United
2007-2015
United States Department of Health and Human Services
2002-2006
National and Kapodistrian University of Athens
2002
Background. Kaposi sarcoma-associated herpesvirus (KSHV) is the causal agent for sarcoma (KS) and multicentric Castleman disease (MCD) in human immunodeficiency virus (HIV)-infected patients. Patients with KSHV-MCD develop fevers, wasting, hypoalbuminemia, cytopenias, hyponatremia that are related to overproduction of KSHV-encoded viral interleukin (IL)-6 (vIL-6) IL-6 (hIL-6).
Background. Kaposi sarcoma herpesvirus (KSHV) is the cause of (KS), primary effusion lymphoma (PEL), and a form Castleman disease (KSHV-MCD). Recently KSHV-associated inflammatory cytokine syndrome (KICS) distinct from KSHV-MCD was reported.
PURPOSE: To assess the toxicity and activity of oral thalidomide in Kaposi’s sarcoma (KS) a phase II dose-escalation study. PATIENTS AND METHODS: Human immunodeficiency virus (HIV)–seropositive patients with biopsy-confirmed KS that progressed over 2 months before enrollment received an initial dose 200 mg/d The was increased to maximum 1,000 for up 1 year. Anti-HIV therapy maintained during study period. Toxicity, tumor response, immunologic angiogenic factors, virologic parameters were...
To investigate the occurrence of non-Hodgkin's lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients receiving long-term antiretroviral therapy and factors associated with development these lymphomas.The charts 55 advanced HIV infection zidovudine (formerly known as azidothymidine [AZT])-based 61 dideoxyinosine (ddI) were examined for NHL. Stored samples from AZT-based treatment cohort retrospectively parameters predictive subsequent lymphoma.Eight developed NHL, yielding an...
Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by sarcoma–associated herpesvirus. Unmet needs include therapies that are oral, anthracycline sparing, and deliverable in resource-limited settings. We evaluated pomalidomide, an oral immune modulatory agent, patients with symptomatic KS. Methods The primary objectives were to assess tolerability, pharmacokinetics, activity. Initial dosage level was 5 mg once per day for 21 days 28-day cycle, de-escalated of 3 if not tolerable,...
Purpose Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes KS pathogenesis. We evaluated the humanized anti–VEGF-A monoclonal antibody, bevacizumab, in HIV-KS. Patients and Methods HIV-KS who either experienced progression while receiving highly active antiretroviral therapy (HAART) at least 1 month or did not regress despite HAART 4 months were administered bevacizumab 15 mg/kg...
PURPOSE To investigate the antitumor activity and safety of paclitaxel in patients with advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS). PATIENTS AND METHODS Twenty-nine HIV-associated KS were enrolled. The overall quite immunosuppressed (median CD4 count, 15 cells/microL). Paclitaxel was initially administered at 135 mg/m2 over 3 hours every weeks without filgrastim support; dose increased as tolerated to a maximum 175 mg/m2. Patients who failed respond or...
We have identified a subset of CD56 + CD3 − human natural killer (NK) cells that express CD4 and the HIV coreceptors CCR5 CXCR4. These can be productively infected in vitro by both CCR5- CXCR4-using molecular clones HIV-1 CD4-dependent manner. Analysis HIV-infected persons showed viral DNA is present purified NK cells, virus could rescued from these after cultivation. Longitudinal analysis levels patients 1–2 years highly active antiretroviral therapy indicated remain persistently account...
Objective: To investigate the relation between CD4 count and immediate hazard of dying in patients receiving zidovudine (azidothymidine [AZT])-based antiretroviral therapy. Setting: A research hospital that recruits from entire United States. Design: Retrospective analysis a cohort with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex participating longterm zidovudine-based protocols. Patients: Fifty-five human virus (HIV) infection either AIDS severe who were followed for...
Several immunodeficiencies are associated with high susceptibility to persistent and progressive human papillomavirus (HPV) infection leading a wide range of cutaneous mucosal lesions. However, the HPV types most commonly such clinical manifestations in these patients have not been systematically defined. Here, we used virion enrichment, rolling circle amplification, deep sequencing identify circular DNA viruses present skin swabs and/or wart biopsy samples from 48 rare genetic...
The Kaposi sarcoma associated herpesvirus (KSHV) genome encodes more than 85 open reading frames (ORFs). Serological evaluation of KSHV infection now generally relies on reactivity to just one latent and/or lytic protein (commonly ORF73 and K8.1). Most the other polypeptides encoded by virus have unknown antigenic profiles. We systematically expressed purified products from 72 ORFs in recombinant systems analyzed seroreactivity US patients with KSHV-associated malignancies, blood donors (low...
A randomized pilot study comparing alternating and simultaneous regimens of zidovudine didanosine (ddl) was conducted in 41 patients with AIDS or symptomatic human immunodeficiency virus (HIV) infection. Patients on each regimen received the same overall amounts over time. CD4 cell counts reached a maximum (mean ± SE) 108 16/mm3 above baseline (two-tailed P ⩾ .0001) were significantly higher than at all time points during weeks 6–45. At 54 weeks, still 40 19/mm3 baseline. also had greater...
We established a method to estimate the amounts of HIV-1 particles in plasma from patients with infection by using polymerase chain reaction (PCR) following reverse transcription (RT) viral RNA (RNA-PCR) and assessed potential usefulness this approach monitor changes load AIDS or AIDS-related complex (ARC) receiving 2′,3′-dideoxyinosine (ddI). Plasma samples were obtained 77 (49 AIDS/ARC 28 asymptomatic seropositives). Following ultracentrifugation plasma, was extracted pelleted virus...
// Romin Roshan 1 , Nazzarena Labo Matthew Trivett Wendell Miley Vickie Marshall Lori Coren Elena M. Cornejo Castro Hannah Perez Benjamin Holdridge Eliza Davis Rodrigo Matus-Nicodemos 2 Victor I. Ayala Raymond Sowder II Kathleen Wyvill 3 Karen Aleman Christine Fennessey Jeffrey Lifson Mark N. Polizzotto Daniel Douek Brandon Keele Thomas S. Uldrick Robert Yarchoan Claes Ohlen David Ott and Denise Whitby AIDS Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for...
A set of five reverse transcriptase mutations, which include Q151M, is known to confer multi-dideoxynucleoside resistance (MDR) in human immunodeficiency virus type 1 (HIV-1). MDR mutations were found 6 (17%) HIV-1 isolates from 36 patients, most whom receiving long-term combination therapy. Q151M was among the first substitutions appear. Additional observed, although none common all patients. Certain zidovudine-related not observed together with indicating possible enzymatic constraint....
Background. Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative inflammatory disorder commonly associated with human immunodeficiency virus (HIV). Its presentation may be difficult to distinguish from HIV and its complications, including lymphoma. Novel imaging strategies could address these problems. Methods. We prospectively characterized 18F-fluorodeoxyglucose positron emission tomography (PET) findings in 27 patients KSHV-MCD....